listings, Refinitiv data shows, well up from the $1.9 billion from 14 deals in the same period a year ago.Įight Chinese companies including home service platform Daojia Ltd and Atour Lifestyle Holdings have made public filings with the Securities and Exchange Commission (SEC) to list in the U.S. So far this year, a record $12.5 billion by Chinese firms has been raised from 34 U.S.Ĭapital markets have been a lucrative source of funding for Chinese firms in the past decade, especially for technology companies looking to benchmark their valuations against listed peers there and tap an abundant liquidity pool. Morgan Stanley, Bank of America, and China International Capital Corp Ltd (CICC) were the investment banks on the deal and all declined to comment to Reuters. LinkDoc did not immediately respond to a request for comment. The sources declined to be identified as the information has not yet been made public. The book closed one day earlier than planned on Wednesday, one of the three sources and a separate person said.
It had planned to sell 10.8 million shares between $17.50 and $19.50 each. and make it more difficult to raise funds overseas," he said.īacked by Alibaba Health Information Technology Ltd, LinkDoc filed for its IPO last month and was due to price its shares after the U.S. "The new rules may impose long waiting periods on any companies hoping to list abroad which will hit investor sentiment, depress valuations for IPOs in the U.S. listing, they may have to wait for further clarification, stricter scrutiny and pre-approval from different regulators and authorities," said Bruce Pang, macro & strategy research head at China Renaissance Securities. LinkDoc's decision to suspend its $211 million IPO, first reported by Reuters, is likely to be followed by others, analysts said, although they noted that U.S.(Yicai Global) July 2 - China's LinkDoc Technology, a medical data company invested by Alibaba Group Holding's healthcare arm, aims to raise up to USD243 million in its initial public offering on the Nasdaq.
The oncology data platform will issue 10.8 million American depositary shares at a price range of USD17.50 to USD19.50, the Beijing-based firm said in its updated prospectus filed with the US Securities and Exchange Commission yesterday. Underwriters may subscribe to an additional 1.6 million ADSs under a greenshoe option. Six investors, including Alibaba Health Hong Kong Technology, have expressed their intentions to buy nearly half of the shares before the IPO, the prospectus added.
0 kommentar(er)
